Low-Dose Creatine Boosts Brain Levels and Cognition in Menopausal Women
A randomized trial finds 1,500 mg/day creatine hydrochloride improves reaction time, frontal brain creatine, and lipid profiles in menopausal women.
Summary
A double-blind RCT in 36 perimenopausal and menopausal women tested two doses of creatine hydrochloride and a creatine hydrochloride-ethyl ester combination against placebo over 8 weeks. The medium dose (1,500 mg/day) outperformed placebo on reaction time, frontal lobe creatine concentrations measured by neuroimaging, and serum lipid profiles. A trend toward reduced mood swing severity was also observed. Low doses well below standard athletic protocols (typically 3–5 g/day) proved effective, suggesting enhanced-solubility creatine forms may be a practical, safe nutritional strategy for the cognitive and metabolic challenges associated with the menopause transition.
Detailed Summary
Menopause is associated with declining estrogen levels that affect cerebral energy metabolism, cognition, mood, and cardiovascular risk — challenges for which safe, accessible interventions remain limited. Creatine plays a central role in brain energy buffering, and lower brain creatine levels have been linked to cognitive decline. This trial examined whether novel, high-solubility creatine formulations at low doses could address these gaps.
The CONCRET-MENOPA trial enrolled 36 apparently healthy perimenopausal and menopausal women (mean age ~50 years) in a randomized, double-blind, placebo-controlled design. Participants received one of four interventions for 8 weeks: low-dose creatine hydrochloride (750 mg/day), medium-dose creatine hydrochloride (1,500 mg/day), a combination of creatine hydrochloride plus creatine ethyl ester (800 mg/day total), or placebo. Cognitive function, brain creatine concentrations, serum biochemistry, and clinical symptoms were assessed before and after the intervention.
The medium-dose creatine hydrochloride group showed the strongest outcomes. Reaction time improved by 1.2% versus a 6.6% worsening in the placebo group (p < 0.01). Frontal brain creatine levels rose by 0.9% compared to a 16.4% decline in placebo (p < 0.01). Serum lipid profiles also improved significantly (p < 0.05), and a near-significant trend toward reduced mood swing severity was noted (p = 0.06). All formulations were well tolerated with no serious adverse events.
These findings are notable because the effective doses are far lower than conventional creatine monohydrate protocols, potentially reducing gastrointestinal side effects and improving adherence. The ability to maintain and elevate brain creatine during a period of natural energetic decline is clinically meaningful.
Key caveats include the small sample size (n=36 across four arms), the short 8-week duration, and the fact that the study is only available as an abstract, limiting full methodological scrutiny. Larger, longer trials are warranted.
Key Findings
- Medium-dose creatine HCl (1,500 mg/day) improved reaction time vs. placebo decline (1.2% vs. 6.6%; p<0.01).
- Frontal brain creatine levels increased with medium-dose vs. a 16.4% drop in the placebo group (p<0.01).
- Serum lipid profiles improved significantly with medium-dose creatine hydrochloride (p<0.05).
- A near-significant trend toward reduced mood swing severity was observed (p=0.06).
- All creatine formulations were well tolerated with no severe adverse effects over 8 weeks.
Methodology
Double-blind, placebo-controlled RCT with 36 perimenopausal and menopausal women randomized to four arms over 8 weeks. Outcomes included cognitive testing, brain creatine levels (likely via MR spectroscopy), serum biomarkers, and symptom assessments. Registered at ClinicalTrials.gov (NCT06660004).
Study Limitations
The trial is small (n=36 across four groups), limiting statistical power and generalizability. The 8-week duration is insufficient to assess long-term safety or sustained cognitive benefit. Full methodology could not be verified as only the abstract was available.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.